ClinicalTrials.gg
Active, not recruitingNCT05925569ALERT-PAUpdated Nov 3, 2026Results posted

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

An interventional study of Best Practice Advisory Computerized Alert in Primary Aldosteronism, Resistant Hypertension and Secondary Hypertension, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Screening

How we know

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12,501
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Hyperaldosteronism with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Hyperaldosteronism · United States.

Started
2024
with 1 other
No phase
2 of 19
none open now
Registered
17th of 19
by date
Lead sponsor
5 of 19
Brigham and Women's Hospital

Among the 19 studies in Hyperaldosteronism with a site in United States, this one is one of 2 that started in 2024, is one of 2 with no phase, and was the 17th registered.

Hyperaldosteronism

201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.

Browse Hyperaldosteronism studies →

Open to participants now

4 of the 19 studies in Hyperaldosteronism with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hyperaldosteronism with a site in United States, or all of them as a file.
02

Study summary

Primary aldosteronism (PA) is common but rarely recognized cause of hypertension that carries excess cardiovascular and renal risk and has approved targeted treatments. Despite current clinical guidelines that recommend screening in a defined set of high-risk populations, less than 5% of eligible patients are ever screened for PA. This study aims to evaluate the impact of a computer decision support Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients, referral to specialist PA care, and treatment with mineralocorticoid receptor antagonists.

Read the detailed description

The study protocol is a single-center Quality Improvement initiative performed as a cluster-randomized controlled trial designed to evaluate the impact of an EPIC electronic health record Best Practice Advisory (BPA) alert on rates of screening for PA in guideline-eligible patients. All patients meeting inclusion/exclusion criteria for Primary Aldosteronism (PA) screening seen over the 12-week enrollment period will comprise the study population, with randomization of alert/no alert occurring at the level of their treating clinician (Attending Physician, Nurse Practitioner, or Physician Assistant) to minimize spillover/contamination effects of the BPA onto other patients treated by the same clinician. Treating clinicians within primary care and relevant specialties including endocrinology, nephrology, and cardiology will be randomized 1:1 to receive or not receive a BPA prompting screening for PA with laboratory testing of plasma aldosterone, plasma renin activity, and a basic metabolic panel, as well as an order for an e-consult to provide guidance on interpretation of results, for eligible patients. Outcomes will be ascertained by electronic health record review at 6 months.

03

Conditions studied

  • Primary Aldosteronism
  • Resistant Hypertension
  • Secondary Hypertension
  • Hyperaldosteronism
  • Mineralocorticoid Excess
  • Hypertension

Keywords

  • Computer Decision Support
  • Primary Aldosteronism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18+
  • Seen by clinician at one of the intervention practices at least once in the prior 2 years
  • History of Hypertension (ICD Code) PLUS ≥1 of the below:

    • Outpatient BP >150/100 on 2 or more occasions
    • Three or more current antihypertensive medication prescriptions
    • Potassium level \<3.5mEq/L or potassium supplement prescription in the last 5 years
    • History of Atrial Fibrillation or Atrial Flutter (ICD Code)

Exclusion criteria

Exclusion Criteria:

  • History of Primary Aldosteronism (ICD Code)
  • Prescription for a Mineralocorticoid Receptor Antagonist (MRA) within the last 3 months
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
12,501 participants (actual)

Study arms

  • Experimental
    BPA Alert Intervention

    An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the clinician that their patient should be screened for Primary Aldosteronism and provides an order set for the corresponding laboratory evaluation. Details of the electronic alert are provided in the Intervention description.

    Other: Best Practice Advisory Computerized Alert

  • No intervention
    No Alert Intervention

    No electronic alert will be issued in the No Intervention group. Providers will continue standard of care with their patients.

Interventions

  • OtherBest Practice Advisory Computerized Alert

    For patients randomly assigned to the BPA Alert Group, an on-screen electronic alert will be issued during the outpatient clinical encounter than notifies the clinician that their patient should be screened for PA. The clinician will be provided with on-screen details of which patient-specific risk factors qualified them for PA screening and with an option to order a plasma renin activity, aldosterone, and basic metabolic panel. If screening labs are ordered, the clinician will also receive an option to order an eConsult for expert guidance on interpretation of the test results. If the clinician does not order the PA screening labs, they will be able to continue with clinical EHR documentation but will need to select a reason they opted not to follow the alert's evidence-based clinical practice recommendation.

06

What researchers measure

Primary outcomes

  1. Frequency of PA Testing Orders by Provider

    The primary outcome is the frequency of aldosterone/renin laboratory testing orders placed by providers.

    Time frame: 6 months

Secondary outcomes

  1. Frequency of PA-related Specialty Referral

    Frequency of referral to specialist who may treat PA (endocrinology, cardiology, or nephrology)

    Time frame: 6 months

  2. Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription

    Frequency of prescription of empiric MRA such as spironolactone, eplerenone, or finerenone

    Time frame: 6 months

  3. Frequency of New PA-related Diagnoses

    Frequency of new ICD Diagnostic Code for PA, Secondary Hypertension, or Endocrine Hypertension

    Time frame: 6 months

  4. Frequency of E-Consult Order by Provider

    Frequency of provider ordering an E-Consult with a PA-specialist

    Time frame: 6 months

  5. Frequency of "Positive" PA Results

    Frequency of a suppressed plasma renin activity \<=1 and aldosterone \>=7.5 among patients who are screened.

    Time frame: 6 months

07

Results

Posted Nov 3, 2026

Participant flow

All patients meeting study eligibility were identified by an automated best practice advisory (BPA) system within the Epic electronic medical record and randomized at the clinician level based on provider NPI during the 12-week enrollment period. Inclusion criteria were primary aldosteronism screening indications and a clinical practitioner in primary care, cardiology, nephrology, or endocrinology. This resulted in a study population of 12501 patients randomized to an active BPA or no alert.

Participant flow — Overall Study
MilestoneBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Started61096392
Completed61096392
Not completed00

Outcome measures

PrimaryFrequency of PA Testing Orders by Provider

The primary outcome is the frequency of aldosterone/renin laboratory testing orders placed by providers.

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of PA Testing Orders by Provider
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of PA Testing Orders by Provider40198
SecondaryFrequency of PA-related Specialty Referral

Frequency of referral to specialist who may treat PA (endocrinology, cardiology, or nephrology)

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of PA-related Specialty Referral
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of PA-related Specialty Referral733746
SecondaryFrequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription

Frequency of prescription of empiric MRA such as spironolactone, eplerenone, or finerenone

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of Empiric Mineralocorticoid Receptor Antagonist (MRA) Prescription143173
SecondaryFrequency of New PA-related Diagnoses

Frequency of new ICD Diagnostic Code for PA, Secondary Hypertension, or Endocrine Hypertension

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of New PA-related Diagnoses
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of New PA-related Diagnoses1312
SecondaryFrequency of E-Consult Order by Provider

Frequency of provider ordering an E-Consult with a PA-specialist

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of E-Consult Order by Provider
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of E-Consult Order by Provider200
SecondaryFrequency of "Positive" PA Results

Frequency of a suppressed plasma renin activity \<=1 and aldosterone \>=7.5 among patients who are screened.

Time frame:
6 months
Reported as:
Count of participants · Participants
Frequency of "Positive" PA Results
ParticipantsBPA Alert Intervention - PatientsNo Alert Intervention - Patients
Frequency of "Positive" PA Results4022

Adverse events

Collected over N/A - Adverse events were not assessed.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BPA Alert Intervention - Patients———
No Alert Intervention - Patients———

Baseline characteristics

Age, Continuous
Age, Continuous(years)BPA Alert Intervention - PatientsNo Alert Intervention - PatientsTotal
Mean69.7 ± 12.971.1 ± 12.970.4 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)BPA Alert Intervention - PatientsNo Alert Intervention - PatientsTotal
Female347533946869
Male263429985632
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BPA Alert Intervention - PatientsNo Alert Intervention - PatientsTotal
American Indian or Alaska Native81119
Asian167161328
Native Hawaiian or Other Pacific Islander257
Black or African American8067381544
White444848079255
More than one race504696
Unknown or Not Reported6286241252
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BPA Alert Intervention - PatientsNo Alert Intervention - PatientsTotal
Hispanic or Latino5706071177
Not Hispanic or Latino5101528010381
Unknown or Not Reported438505943
08

Study locations

1 site
09

References and documents

Publications

  • Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary Aldosteronism: State-of-the-Art Review. Am J Hypertens. 2022 Dec 8;35(12):967-988. doi: 10.1093/ajh/hpac079. PubMed 35767459 ↗
  • Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50. doi: 10.1016/S2213-8587(17)30319-4. Epub 2017 Nov 9. PubMed 29129575 ↗
  • Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020 Jul 7;173(1):10-20. doi: 10.7326/M20-0065. Epub 2020 May 26. PubMed 32449886 ↗
  • Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2. PubMed 26934393 ↗
  • Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Ann Intern Med. 2021 Mar;174(3):289-297. doi: 10.7326/M20-4873. Epub 2020 Dec 29. PubMed 33370170 ↗
  • Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, Carroll B, Landman AB, Emani S, Goldhaber SZ. Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). Eur Heart J. 2020 Mar 7;41(10):1086-1096. doi: 10.1093/eurheartj/ehz385. PubMed 31228189 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Dec 2024, 8 months.

Results were first posted in Nov 2026, 1 year 10 months after primary completion.

Of 36 interventional studies with no phase under Hyperaldosteronism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jun 29, 2023
StartActual
Mar 13, 2024
Primary completionActual
Dec 9, 2024
CompletionEst.
Dec 31, 2029
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFrequency of PA testing ordersTesting Orders by providerProviderTime frame: 6 months
Nov 3, 2026
Documents
Secondary outcomes
3 edited, 1 removed, 1 description edited
What changed in the outcomes
  • EditedFrequency of newNew PA-related diagnosesDiagnosesTime frame: 6 months
  • EditedFrequency of E-Consult orderOrder by providerProviderTime frame: 6 months
  • EditedFrequency of "Positive" PA resultsResultsTime frame: 6 months
  • DescriptionFrequency of PA-related Specialty Referral: how it is measured was reworded
  • Removedother outcomeChange in Systolic Blood PressureTime frame: 6 months
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFrequency of PA testing ordersTesting Orders by providerProviderTime frame: 6 months
    Secondary outcomes 3 edited, 1 removed, 1 description edited
    What changed in the outcomes
    • EditedFrequency of newNew PA-related diagnosesDiagnosesTime frame: 6 months
    • EditedFrequency of E-Consult orderOrder by providerProviderTime frame: 6 months
    • EditedFrequency of "Positive" PA resultsResultsTime frame: 6 months
    • DescriptionFrequency of PA-related Specialty Referral: how it is measured was reworded
    • Removedother outcomeChange in Systolic Blood PressureTime frame: 6 months
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05925569
Responsible party
Jenifer M. Brown, M.D. (Associate Physician, Brigham and Women's Hospital) — Principal investigator
First posted
Jun 29, 2023
Start date
Mar 13, 2024
Primary completion
Dec 9, 2024
Completion
Dec 31, 2029 (estimated)
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Jenifer M Brown, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion